Ownership history in BML Capital Management, LLC Β· 8 quarters on record
This page tracks every 13F SEC filing in which BML Capital Management, LLC reported a position in INSTIL BIO INC (TIL). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π BML Capital Management, LLC outperformed the S&P 500 by +276.9% annually on this TIL position. Timing score: 50% (3/6 decisions correct). Average cost basis: $18.15. Maximum drawdown during holding period: β83.7%.
π₯ Exceptional β beat the S&P 500 by 276.9% per year on this position.
6 quarters analyzed
β‘οΈ Neutral timing β roughly coin-flip accuracy on add/trim calls.
3 of 6 add/trim decisions correct
Best entry: $10.29 (2024 Q2) Β· Worst: $20.83 (2025 Q2)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
6 adds Β· 1 trim. Bought during 3 of 4 down-price quarters. π Consistently bullish β fund kept accumulating this position.
π BML Capital Management, LLC has been actively increasing its TIL allocation β a bullish signal from insiders.
Currently 6.14% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size